18th European Headache Congress

Fremanezumab for the prevention of menstrually-related migraine attacks – a prospective observational phase 4 study according to routine neurological care in Switzerland (FROMM)

Sex and gender

ePoster 06

ePoster

Impact of Fremanezumab cessation and reinitiation in migraine management: PEARL study 4th interim analysis

Migraine

ePoster 01

First, we will give a brief overview of the hormone fluctuations in the menstrual cycle and the properties of different therapeutical hormones used for contraception, perimenopause symptoms, endometriosis treatment, and hormone replacement in menopause or early menopause. Then, we will dive into the clinical management of three women with migraine ranging from adolescence to menopause. The discussion will center on the positive or negative effects of the various hormones in respect of both, the gynecologic needs and the effect on migraine.The aim is to allow the migraine specialist to better understand and manage the hormonal mechanisms of migraine in women at different ages.Participants are invited to contribute with own cases to a lively discussion. Prof. Dr Gabriele Susanne Merki-Feld is a Gynaecologic Endocrinologist with over 30 years of experience. She has conducted intensive research into contraception, hormone-induced migraines and endometriosis, published over 50 scientific articles and received the Hans Ruedi Isler Prize in 2017. She has been working in neurology at the University of Bern since 2024.

Christoph J. Schankin

Einsätze

05.12.